Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers.

Abstract

BACKGROUND:

Treatment options for patients with metastatic uterine leiomyosarcoma are limited. Over the last few years, trabectedin has emerged as an effective agent for patients with advanced soft tissue sarcomas resistant to anthracyclines and ifosfamide. The aim of this retrospective analysis was to look at the efficacy of trabectedin in the subgroup of uterine leiomyosarcoma.

PATIENTS AND METHODS:

A retrospective analysis was carried out on patients with uterine leiomyosarcoma treated with trabectedin at two reference sarcoma centers between 2000 and 2010. Radiological response, progression-free and overall survival, as well as serious and unexpected adverse events, were assessed.

RESULTS:

Sixty-six patients with metastatic uterine leiomyosarcoma were identified. The median number of previous chemotherapy regimens was 3 (range 1-5). Eleven patients (16%) achieved a partial response and 23 (35%) had a stable disease. The progression-free survival of the entire cohort was 3.3 months (CI 95% 2-5), and the progression-free rate at 3 and 6 months was 53% and 33%, respectively.

CONCLUSIONS:

Trabectedin is a therapeutic option in the palliative approach to the metastatic uterine leiomyosarcoma patient.

• Authors: Roberta Sanfilippo, Federica Grosso, Robin L Jones, Susana Banerjee, Silvana Pilotti, Maurizio D'Incalci, Angelo Paolo Dei Tos, Francesco Raspagliesi, Ian Judson, Paolo Giovanni Casali
• Journal: Gynecologic oncology (Gynecol Oncol) Vol. 123 Issue 3 Pg. 553-6 (Dec 2011) ISSN: 1095-6859 [Electronic] United States
• PMID: 21917307 (Publication Type: Journal Article, Multicenter Study)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Antineoplastic Agents, Alkylating
• Dioxoles
• Tetrahydroisoquinolines
• Trabectedin

Topics

• Adult
• Aged
• Antineoplastic Agents, Alkylating (adverse effects, therapeutic use)
• Combined Modality Therapy
• Dioxoles (adverse effects, therapeutic use)
• Disease-Free Survival
• Female
• Humans
• Leiomyosarcoma (drug therapy, surgery)
• Middle Aged
• Retrospective Studies
• Survival Rate
• Tetrahydroisoquinolines (adverse effects, therapeutic use)
• Trabectedin
• Uterine Neoplasms (drug therapy, surgery)